Published in J Biol Chem on February 10, 1970
Mutant defective in processing of an enzyme located in the lysosome-like vacuole of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1981) 4.20
Isolation of a glucagon-containing peptide: primary structure of a possible fragment of proglucagon. Proc Natl Acad Sci U S A (1973) 1.73
Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci U S A (1983) 1.51
Early differentiation of glucagon-producing cells in embryonic pancreas: a possible developmental role for glucagon. Proc Natl Acad Sci U S A (1973) 1.26
Distribution of the gut hormones in the primate intestinal tract. Gut (1979) 1.10
Biosynthesis of glucagon in isolated pancreatic islets of guinea pigs. Biochem J (1974) 1.08
Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure. J Clin Invest (1976) 1.08
Pathogenesis and characterization of hyperglucagonemia in the uremic rat. J Clin Invest (1976) 0.92
Studies on the biosynthesis of pancreatic glucagon in the pigeon (Columba livia). Biochem J (1976) 0.90
The glycogenolytic activity of immunoreactive pancreatic glucagon in plasma. J Clin Invest (1971) 0.89
The biosynthesis of glucagon in perfused rat pancreas. Biochem J (1973) 0.88
Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources. J Clin Invest (1978) 0.87
Processing of enkephalin-containing peptides in isolated bovine adrenal chromaffin granules. Proc Natl Acad Sci U S A (1983) 0.85
Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. J Clin Invest (1980) 0.83
The purification and biological properties of pancreatic big glucagon. Biochem J (1976) 0.81
Glucagon metabolism in the rat. J Clin Invest (1978) 0.80
Secretion by glucagonomas of a possible glucagon precursor. J Clin Invest (1977) 0.80
The conversion of proinsulin into insulin in the -cells of mammals and fishes. Biochem J (1971) 0.75
Dominant inheritance of large molecular weight immunoreactive glucagon. J Clin Invest (1978) 0.75
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med (1994) 9.15
A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med (1993) 6.52
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A (1998) 4.72
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 3.42
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med (1970) 3.27
Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A (1997) 3.07
Functional subdivision of islets of Langerhans and possible role of D cells. Lancet (1975) 2.83
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest (1968) 2.60
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem (1998) 2.59
Glucagon levels and metabolic effects in fasting man. J Clin Invest (1970) 2.58
The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet (1975) 2.54
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest (1984) 2.52
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 2.48
Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. J Clin Invest (1968) 2.46
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem (1995) 2.43
The impact of weekends on outcome for acute exacerbations of COPD. Eur Respir J (2011) 2.40
Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation (1999) 2.20
The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest (1971) 2.15
Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci U S A (1996) 2.15
Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access. Eur Heart J (2000) 2.13
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med (1990) 2.01
Nocturnal oximetry for the diagnosis of the sleep apnoea hypopnoea syndrome: a method to reduce the number of polysomnographies? Thorax (1999) 1.95
Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes (1982) 1.94
Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A (1999) 1.92
Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation (2000) 1.91
Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med (1979) 1.88
Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes (1969) 1.86
Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes (1971) 1.85
Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes. Science (1990) 1.85
Physiology and pathophysiology of glucagon. Physiol Rev (1976) 1.79
A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med (1966) 1.79
Entero-insular axis. Arch Intern Med (1969) 1.74
Glucagon: role in the hyperglycemia of diabetes mellitus. Science (1975) 1.72
The role of aminogenic glucagon secretion in blood glucose homeostasis. J Clin Invest (1969) 1.71
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest (1968) 1.71
Control of pancreatic glucagon secretion by glucose. Diabetes (1969) 1.69
Glucagon physiology and pathophysiology in the light of new advances. Diabetologia (1985) 1.69
Novel form of lipolysis induced by leptin. J Biol Chem (1999) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes (1997) 1.66
Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med (1973) 1.66
Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med (1981) 1.66
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med (1973) 1.62
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci U S A (1997) 1.59
Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci U S A (1976) 1.59
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Calmodulin activation of adenylate cyclase in pancreatic islets. Science (1979) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Hyperglucagonaemia after burns. Lancet (1974) 1.56
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A (1998) 1.53
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem (1996) 1.53
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost (2005) 1.53
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia (1995) 1.52
The stimulus-secretion coupling of glucose-induced insulin release. XXXV. The links between metabolic and cationic events. Diabetologia (1979) 1.52
The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes (1976) 1.51
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A (1990) 1.51
Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest (1992) 1.50
In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol (2000) 1.49
Coronary stenting in diabetics: immediate and mid-term clinical outcome. Catheter Cardiovasc Interv (1999) 1.48
More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling. Diabetes (1994) 1.45
Effects of secretin on insulin and glucagon in portal and peripheral blood in man. Lancet (1966) 1.44
Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Cathet Cardiovasc Diagn (1996) 1.43
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol (2002) 1.42
Meticulous control of diabetes: benefits, risks, and precautions. Diabetes (1982) 1.41
Nine-year follow-up of balloon-expandable Palmaz-Schatz stent in patients with single-vessel disease. Catheter Cardiovasc Interv (2000) 1.41
A novel leptin receptor isoform in rat. FEBS Lett (1996) 1.40
Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail. J Am Coll Cardiol (1995) 1.40
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia (2004) 1.40
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem (1998) 1.39
PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A (2002) 1.39
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. J Clin Invest (1974) 1.39
Glucagon physiology and pathophysiology. N Engl J Med (1971) 1.38
Structural coupling between pancreatic islet cells. Experientia (1973) 1.37
The riddle of tumor hypoglycemia. Am J Med (1966) 1.35
Effect of secretin on insulin secretion. Lancet (1966) 1.35
Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism (1966) 1.35
Regulation of beta-cell glucose transporter gene expression. Proc Natl Acad Sci U S A (1990) 1.34
beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes (1997) 1.33
Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Physicians (1966) 1.32
Half-life of somatostatin-like immunoreactivity in canine plasma. Endocrinology (1979) 1.32
Specific endocrine and hormonal receptor changes associated with liver regeneration in adult rats. Proc Natl Acad Sci U S A (1975) 1.31
Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. Diabetes (1998) 1.31
Pronase effect on pancreatic beta cell secretion and morphology. Science (1973) 1.31
Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol (1997) 1.31
[Validation of the Spanish version of the Epworth Sleepiness Scale in patients with a sleep apnea syndrome]. Arch Bronconeumol (1999) 1.30
Active hepatic glycogen synthesis from gluconeogenic precursors despite high tissue levels of fructose 2,6-bisphosphate. J Biol Chem (1986) 1.29
Characterization of glucagon-like immunoreactivity (GLI). Diabetes (1970) 1.29